Literature DB >> 23066155

The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Kritika Kachapati1, David E Adams, Yuehong Wu, Charles A Steward, Daniel B Rainbow, Linda S Wicker, Robert S Mittler, William M Ridgway.   

Abstract

CD137 is a T cell costimulatory molecule encoded by the prime candidate gene (designated Tnfrsf9) in NOD.B10 Idd9.3 congenic mice protected from type 1 diabetes (T1D). NOD T cells show decreased CD137-mediated T cell signaling compared with NOD.B10 Idd9.3 T cells, but it has been unclear how this decreased CD137 T cell signaling could mediate susceptibility to T1D. We and others have shown that a subset of regulatory T cells (Tregs) constitutively expresses CD137 (whereas effector T cells do not, and only express CD137 briefly after activation). In this study, we show that the B10 Idd9.3 region intrinsically contributes to accumulation of CD137(+) Tregs with age. NOD.B10 Idd9.3 mice showed significantly increased percentages and numbers of CD137(+) peripheral Tregs compared with NOD mice. Moreover, Tregs expressing the B10 Idd9.3 region preferentially accumulated in mixed bone marrow chimeric mice reconstituted with allotypically marked NOD and NOD.B10 Idd9.3 bone marrow. We demonstrate a possible significance of increased numbers of CD137(+) Tregs by showing functional superiority of FACS-purified CD137(+) Tregs in vitro compared with CD137(-) Tregs in T cell-suppression assays. Increased functional suppression was also associated with increased production of the alternatively spliced CD137 isoform, soluble CD137, which has been shown to suppress T cell proliferation. We show for the first time, to our knowledge, that CD137(+) Tregs are the primary cellular source of soluble CD137. NOD.B10 Idd9.3 mice showed significantly increased serum soluble CD137 compared with NOD mice with age, consistent with their increased numbers of CD137(+) Tregs with age. These studies demonstrate the importance of CD137(+) Tregs in T1D and offer a new hypothesis for how the NOD Idd9.3 region could act to increase T1D susceptibility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23066155      PMCID: PMC3505683          DOI: 10.4049/jimmunol.1101013

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.

Authors:  Rebecca S McHugh; Matthew J Whitters; Ciriaco A Piccirillo; Deborah A Young; Ethan M Shevach; Mary Collins; Michael C Byrne
Journal:  Immunity       Date:  2002-02       Impact factor: 31.745

2.  Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis.

Authors:  G-Z Liu; A C Gomes; P Putheti; V Karrenbauer; K Kostulas; R Press; J Hillert; P Hjelmström; X-G Gao
Journal:  Scand J Immunol       Date:  2006-10       Impact factor: 3.487

3.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

4.  Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes.

Authors:  Jennifer L Cannons; Giselle Chamberlain; Joanna Howson; Luc J Smink; John A Todd; Laurence B Peterson; Linda S Wicker; Tania H Watts
Journal:  J Autoimmun       Date:  2005-08       Impact factor: 7.094

5.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion.

Authors:  Petra Hoffmann; Ruediger Eder; Tina J Boeld; Kristina Doser; Biserka Piseshka; Reinhard Andreesen; Matthias Edinger
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

6.  Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes.

Authors:  Junichiro Irie; Yuehong Wu; Kritika Kachapati; Robert S Mittler; William M Ridgway
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

Review 7.  TNF/TNFR family members in costimulation of T cell responses.

Authors:  Tania H Watts
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

8.  Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells.

Authors:  Felicita Baratelli; Ying Lin; Li Zhu; Seok-Chul Yang; Nathalie Heuzé-Vourc'h; Gang Zeng; Karen Reckamp; Mariam Dohadwala; Sherven Sharma; Steven M Dubinett
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

9.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function.

Authors:  Lauren W Collison; Creg J Workman; Timothy T Kuo; Kelli Boyd; Yao Wang; Kate M Vignali; Richard Cross; David Sehy; Richard S Blumberg; Dario A A Vignali
Journal:  Nature       Date:  2007-11-22       Impact factor: 49.962

10.  Where CD4+CD25+ T reg cells impinge on autoimmune diabetes.

Authors:  Zhibin Chen; Ann E Herman; Michael Matos; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2005-11-21       Impact factor: 14.307

View more
  23 in total

1.  Idd13 is involved in determining immunoregulatory DN T-cell number in NOD mice.

Authors:  V Dugas; A Liston; E E Hillhouse; R Collin; G Chabot-Roy; A-N Pelletier; C Beauchamp; K Hardy; S Lesage
Journal:  Genes Immun       Date:  2014-01-16       Impact factor: 2.676

2.  Congenic mapping identifies a novel Idd9 subregion regulating type 1 diabetes in NOD mice.

Authors:  Bixuan Lin; Ashley E Ciecko; Erin MacKinney; David V Serreze; Yi-Guang Chen
Journal:  Immunogenetics       Date:  2016-10-28       Impact factor: 2.846

3.  Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.

Authors:  Margaret M Lowe; Ian Boothby; Sean Clancy; Richard S Ahn; Wilson Liao; David N Nguyen; Kathrin Schumann; Alexander Marson; Kelly M Mahuron; Gillian A Kingsbury; Zheng Liu; Priscila Munoz Sandoval; Robert Sanchez Rodriguez; Mariela L Pauli; Keyon Taravati; Sarah T Arron; Isaac M Neuhaus; Hobart W Harris; Esther A Kim; Uk Sok Shin; Matthew F Krummel; Adil Daud; Tiffany C Scharschmidt; Michael D Rosenblum
Journal:  JCI Insight       Date:  2019-12-19

4.  CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice.

Authors:  Matthew H Forsberg; Ashley E Ciecko; Kyle J Bednar; Arata Itoh; Kritika Kachapati; William M Ridgway; Yi-Guang Chen
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

5.  Evidence of genetic epistasis in autoimmune diabetes susceptibility revealed by mouse congenic sublines.

Authors:  Roxanne Collin; Véronique Dugas; Adam-Nicolas Pelletier; Geneviève Chabot-Roy; Sylvie Lesage
Journal:  Immunogenetics       Date:  2021-03-23       Impact factor: 2.846

6.  Genome-wide transcriptional analyses of islet-specific CD4+ T cells identify Idd9 genes controlling diabetogenic T cell function.

Authors:  Gregory J Berry; Christine Frielle; Thaiphi Luu; Anna C Salzberg; Daniel B Rainbow; Linda S Wicker; Hanspeter Waldner
Journal:  J Immunol       Date:  2015-02-11       Impact factor: 5.422

7.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 8.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development.

Authors:  Kenji Hashimoto
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

10.  The non-obese diabetic mouse sequence, annotation and variation resource: an aid for investigating type 1 diabetes.

Authors:  Charles A Steward; Jose M Gonzalez; Steve Trevanion; Dan Sheppard; Giselle Kerry; James G R Gilbert; Linda S Wicker; Jane Rogers; Jennifer L Harrow
Journal:  Database (Oxford)       Date:  2013-05-31       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.